Study Shows Promise of Sotorasib in Treating Vascular Malformations Linked to Genetic Mutation

A breakthrough study published in the New England Journal of Medicine reveals promising results of using sotorasib, a KRAS G12C inhibitor, to reduce vascular malformations associated with a specific genetic mutation. Led by Antoine Fraissenon, M.D., and Guillaume Canaud, M.D., Ph.D., the research demonstrates significant reductions in malformation size and improved survival rates in mouse models and adult patients. This breakthrough highlights the potential of targeting the KRAS G12C mutation as a therapeutic approach for individuals with related vascular malformations.